Collateral circulation

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chief scientific officer, Collateral circulation, DMAC, University, Senior, Internal medicine, Patient-Centered Outcomes Research Institute, Harvard T.H. Chan School of Public Health, Stroke, TPA, Harvard University, Associate, Bangladesh Technical Education Board, Harvard Medical School, NYSE, Master of Science, Public health, Miami University, Publication, National academy, Beth Israel Hospital, Patient, Division, Neuromodulation, PCORI, Executive Committee, Case Western Reserve University School of Medicine, S-1 Executive Committee, Biostatistics, HEAL, Neurology, NIH, Interventional cardiology, Pharmaceutical industry, Nursing, Science, Medtronic, Brigham, Parkland Memorial Hospital, Medicine

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
  • Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee.
  • Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009.
  • Before joining Medtronic, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston.

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

Retrieved on: 
Tuesday, April 11, 2023
Health, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Acceleration, Collateral circulation, DMAC, Investment banking, Initial public offering, Employment, University, KLK1, Purple Heart, Stroke, The Purple Heart, Brain, AIS, Sale, Partner, Patient, CBO, United States Department of the Army, Iraq War, Capital Group Companies, Pharmaceutical industry, Security (finance)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO).

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO).
  • In this position, he will lead business development, including financing and partnering strategies, and acceleration of prioritized development programs, as well as other business operations.
  • “Dave brings over 15 years of relevant life sciences, M&A, capital markets, and investor relations experience to DiaMedica.
  • Prior to joining Craig-Hallum, Mr. Wambeke was enlisted in the U.S. Army and served as an artilleryman and military police officer.

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, AIS, Brain, Vasodilation, Trial of the century, Tissue, Safety, Patient, Oxygen, PEGylation, Clinical trial, ISC, Ambient occlusion, Interventional Neuroradiology, Collateral circulation, Plasma, Baptist Health, Principal, Medication, Pharmaceutical industry, Prolonged exposure therapy

Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.

Key Points: 
  • Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.
  • PP-007 (PEGylated carboxyhemoglobin, bovine) is a novel investigational biopharmaceutical product that improves microvascular perfusion while promoting transfer of oxygen to oxygen-deprived (hypoxic) cells and tissues.
  • HEMERA-1 is the first clinical trial of PP-007 in AIS.
  • PP-007’s multi-modal mechanism of action includes (1) increased blood flow and vasodilation of collateral circulation, (2) targeted delivery of oxygen in ischemic areas for 24 hours, and (3) plasma expansion.

Brainomix's AI Software to be Rolled Out Across Hungary's Entire National Healthcare System to Improve Stroke Care

Retrieved on: 
Thursday, September 1, 2022
Erad, Cancer, National Institute, Program, Collateral circulation, Artificial intelligence, Associate, Thrombectomy, Department of Neurology, Xuanwu hospital, Precision medicine, CT, Collection, Physician, Department, Diagnosis, European Union response to the COVID-19 pandemic, Ischemia, NHS, Hospital, OXFORD, Ignaz Semmelweis, Neurology, Conference, Stroke, Algorithm, Mental health, Congress, National Institute of Mental Health, EFOP, Society, Patient, Pharmaceutical industry, Medical device, EU, Health, Neurosurgery

Awarded following a competitive process, the 5-year program is funded under the EU4Health programme and is the first time that a single stroke AI imaging platform will be deployed across an entire country.

Key Points: 
  • Awarded following a competitive process, the 5-year program is funded under the EU4Health programme and is the first time that a single stroke AI imaging platform will be deployed across an entire country.
  • It will enable e-Stroke to be deployed across the remaining 28 stroke centers in Hungary's national healthcare system, with the support of eRAD, who will be serving as a technological partner.
  • Launching the program, Prof Dr Szikora said, "Each year more than 20,000 stroke patients are admitted to hospitals across Hungary.
  • Dr Michalis Papadakis, Brainomix's Chief Executive Officer & Co-Founder, commented, "We are absolutely delighted that e-Stroke has been chosen to help improve stroke care in Hungary.

Brainomix's AI Software to be Rolled Out Across Hungary's Entire National Healthcare System to Improve Stroke Care

Retrieved on: 
Thursday, September 1, 2022
Erad, Cancer, National Institute, Program, Collateral circulation, Artificial intelligence, Associate, Thrombectomy, Department of Neurology, Xuanwu hospital, Precision medicine, CT, Collection, Physician, Department, Diagnosis, European Union response to the COVID-19 pandemic, Ischemia, NHS, Hospital, OXFORD, Ignaz Semmelweis, Neurology, Conference, Stroke, Algorithm, Mental health, Congress, National Institute of Mental Health, EFOP, Society, AI, Patient, Pharmaceutical industry, Medical device, EU, Health, Neurosurgery

Awarded following a competitive process, the 5-year program is funded under the EU4Health programme and is the first time that a single stroke AI imaging platform will be deployed across an entire country.

Key Points: 
  • Awarded following a competitive process, the 5-year program is funded under the EU4Health programme and is the first time that a single stroke AI imaging platform will be deployed across an entire country.
  • It will enable e-Stroke to be deployed across the remaining 28 stroke centers in Hungary's national healthcare system, with the support of eRAD, who will be serving as a technological partner.
  • Launching the program, Prof Dr Szikora said, "Each year more than 20,000 stroke patients are admitted to hospitals across Hungary.
  • Dr Michalis Papadakis, Brainomix's Chief Executive Officer & Co-Founder, commented, "We are absolutely delighted that e-Stroke has been chosen to help improve stroke care in Hungary.